NKX2-1 and lung adenocarcinoma: We therefore suggest that IKKβ inhibitor might have the potential to improve tumour regression and outcomes in p53-mutant lung adenocarcinoma patients with high-NKX2-1 tumours or p53-WT lung adenocarcinoma patients with low-NKX2-1 tumours.